Co-Authors
This is a "connection" page, showing publications co-authored by RONALD A DEPINHO and GIANNICOLA GENOVESE.
Connection Strength
1.001
-
Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment. Cancer Discov. 2020 04; 10(4):608-625.
Score: 0.187
-
Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature. 2017 02 16; 542(7641):362-366.
Score: 0.152
-
Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature. 2017 02 02; 542(7639):119-123.
Score: 0.151
-
Corrigendum: Passenger deletions generate therapeutic vulnerabilities in cancer. Nature. 2015 Sep 10; 525(7568):278.
Score: 0.136
-
Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. Cancer Cell. 2015 May 11; 27(5):644-57.
Score: 0.135
-
Passenger deletions generate therapeutic vulnerabilities in cancer. Nature. 2012 Aug 16; 488(7411):337-42.
Score: 0.111
-
In?Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Cell Rep. 2016 06 28; 16(1):133-147.
Score: 0.036
-
Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer Res. 2015 Mar 15; 75(6):1091-101.
Score: 0.033
-
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014 Oct 30; 514(7524):628-32.
Score: 0.032
-
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 2012 Apr 15; 26(8):756-84.
Score: 0.027